<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200602</url>
  </required_header>
  <id_info>
    <org_study_id>MC0896</org_study_id>
    <secondary_id>NCI-2010-01938</secondary_id>
    <secondary_id>09-007533</secondary_id>
    <secondary_id>MC0896</secondary_id>
    <nct_id>NCT01200602</nct_id>
  </id_info>
  <brief_title>Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy</brief_title>
  <official_title>A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Megestrol acetate may help improve appetite and lessen weight loss caused by
      cancer. PURPOSE: This clinical trial studies megestrol acetate in treating weight loss or
      anorexia in young patients with malignancies who are undergoing radiation therapy and/or
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:Proportion of Patients Who Maintain Weight or Experience Weight Gain.

      SECONDARY OBJECTIVES:BMI Trends, Caloric Intake, Weight Maintenance Over Time, Toxicity
      Profile as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive oral
      megestrol acetate 1-2 times (10 mg/kg dose if once daily or 5 mg/kg dose if twice daily)
      daily for 4 weeks. ARM B (control): Patients are observed for weight loss and gain for 4
      weeks. After completion of study treatment, patients are followed up for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study closed due to slow accrual.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Maintain Weight or Experience Weight Gain</measure>
    <time_frame>4 weeks</time_frame>
    <description>A patient will be defined as &quot;success&quot; if he/she maintains or gains weight at the end if Initial Treatment compared with baseline of study entry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI Trends</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric Intake</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Maintenance Over Time</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients with grade 3+ non-hematologic adverse events using Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Anorexia</condition>
  <condition>Weight Changes</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megestrol acetate</intervention_name>
    <description>Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>BDH 1298</other_name>
    <other_name>Maygace</other_name>
    <other_name>Megace</other_name>
    <other_name>Megestil</other_name>
    <other_name>Niagestin</other_name>
    <other_name>Pallace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical observation</intervention_name>
    <description>No treatment is given.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>observation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any pediatric patient with an underlying diagnosis of a malignancy (excluding
             hematological malignancies like leukemias and lymphomas)

          -  ≥5% weight loss from diagnosis of primary malignancy (must be currently on
             chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5%
             weight loss following bone marrow transplant (autologous or allogeneic blood/bone
             marrow) and not actively receiving corticosteroid therapy

          -  Negative pregnancy test done =&lt; 7 days prior to registration for women of childbearing
             potential only

        Exclusion Criteria:

          -  Receiving tube feedings or parenteral nutrition

          -  Evidence of ascites

          -  Current (within the past 28 days) or planned treatment with adrenal steroids
             (short-term use of dexamethasone around days of intravenous chemotherapy is allowed
             for protection against emesis), androgens, progestational agents, or appetite
             stimulants (e.g., dronabinol)

          -  Known mechanical obstruction of the alimentary tract, malabsorption, or intractable
             vomiting (&gt; 5 episodes/week)

          -  History of unresectable brain tumor or cancer metastatic to the brain

          -  History of thromboembolic disease

          -  Insulin-requiring diabetes

          -  Congestive heart failure and/or uncontrolled hypertension

          -  Anticoagulation

          -  Previous history of thrombosis (personal and immediate family)

          -  Concurrent corticosteroid therapy (except as an antiemetic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vilmarie Rodriguez, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <results_first_submitted>March 29, 2013</results_first_submitted>
  <results_first_submitted_qc>March 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 24, 2013</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One patient was accrued between March 2, 2011 and January 10, 2012. Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</description>
          <units>participants</units>
          <param>Number</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</description>
          <units>participants</units>
          <param>Number</param>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Maintain Weight or Experience Weight Gain</title>
        <description>A patient will be defined as “success” if he/she maintains or gains weight at the end if Initial Treatment compared with baseline of study entry.</description>
        <time_frame>4 weeks</time_frame>
        <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Maintain Weight or Experience Weight Gain</title>
          <description>A patient will be defined as “success” if he/she maintains or gains weight at the end if Initial Treatment compared with baseline of study entry.</description>
          <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI Trends</title>
        <time_frame>4 weeks</time_frame>
        <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>BMI Trends</title>
          <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caloric Intake</title>
        <time_frame>4 weeks</time_frame>
        <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Caloric Intake</title>
          <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Maintenance Over Time</title>
        <time_frame>4 weeks</time_frame>
        <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Maintenance Over Time</title>
          <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile</title>
        <description>Number of patients with grade 3+ non-hematologic adverse events using Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.0</description>
        <time_frame>4 weeks</time_frame>
        <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile</title>
          <description>Number of patients with grade 3+ non-hematologic adverse events using Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.0</description>
          <population>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Patients have clinical observation for weight loss and gain for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vilmarie Rodriguez, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2695</phone>
      <email>rodriguez.vilmarie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

